Penumbra develops and manufactures medical devices for treating vascular and neurovascular conditions, including thrombectomy systems for removing blood clots.
| Filer | 13FScore | This quarter | Shares | Value | % of their book |
|---|---|---|---|---|---|
| Steve Cohen / Point72 | 76 | New buy | 6,557 | $2,070,373 | 0.0% |
| Ancora | 40 | Holds (flat) | 10 | $3,157 | 0.0% |
| Paul Tudor Jones / Tudor | 63 | Trimmed -3% | 400,649 | $126,504,922 | 0.2% |
| Bridgewater | 56 | Trimmed -84% | 1,580 | $498,885 | 0.0% |
| Trade date | Who | Type | Amount | |
|---|---|---|---|---|
| 2026-08-22 | Trump, Donald J President | SELL | $1,001 - $15,000 | PTR |
| 2026-07-01 | Trump, Donald J President | SELL | $1,001 - $15,000 | PTR |
| 2026-07-01 | Trump, Donald J President | BUY | $1,001 - $15,000 | PTR |
Every tracked holder of this name, sorted new → added → flat → trimmed. Shares = reported 13F share count; Value as reported (a few managers file values in $thousands). Generated 2026-09-24.